algorithms.eod_public.1.0.tables.ss2018_hemeretic_3793.json Maven / Gradle / Ivy

{
  "id" : "ss2018_hemeretic_3793",
  "algorithm" : "eod_public",
  "version" : "1.0",
  "name" : "SS2018: HemeRetic",
  "title" : "Summary Stage 2018: HemeRetic",
  "subtitle" : "Summary Stage 2018",
  "notes" : "**Note 1:** The following sources were used in the development of this schema\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/)\n* Collaborative Stage Data Collection System, version 02.05:  https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 83 *Leukemia*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** The following histologies can be localized (code 1), systemic (7) or unknown (9)**\n\n9740  Mast cell sarcoma \n9751 Langerhans cell histiocytosis, disseminated (except C700-C729, C751-C753)\n9755 Histiocytic sarcoma (except C700-C729, C751-C753)\n9756  Langerhans cell sarcoma (except C700-C729, C751-C753)\n9757  Interdigitating dendritic cell sarcoma (except C700-C729, C751-C753)\n9758  Follicular dendritic cell sarcoma (except C700-C729, C751-C753)\n9759  Fibroblastic reticular cell tumor (except C700-C729, C751-C753)\n9930  Myeloid sarcoma  (except C441, C690, C695-C696)\n9971  Polymorphic PTLD \n\n**Note 3:** For histologies listed in **Note 1**, it is possible to have lymph node involvement; however, at this time, lymph node involvement for these histologies is not collected.\n\n**Note 4:** **The following histologies are systemic (code 7):**\n\n9591 Splenic B-cell lymphoma/leukemia, unclassifiable\n9724 Systemic EBV-positive T-cell lymphoma of childhood\n9727 Blastic plasmacytoid dendritic cell neoplasm\n9740 Mast cell sarcoma\n9741 Systemic mastocytosis with an associated hematological neoplasm\n9742 Mast cell leukemia\n9762 Heavy chain diseases\n9800 Leukemia, NOS\n9801 Acute undifferentiated leukemia\n9806 Mixed-phenotype acute leukemia with t(9;22)(q34.1;q11.2); *BCR-ABL1*\n9807 Mixed-phenotype acute leukemia with t(v;11q23.3); *KMT2A*-rearranged\n9808 Mixed -phenotype acute leukemia, B/myeloid, NOS\n9809 Mixed-phenotype acute leukemia, T/myeloid, NOS\n9811 B-lymphoblastic leukemia/lymphoma, NOS\n9812 B-lymphoblastic leukemia/lymphoma with t(9;22))q34.1;q11.2); *BCR-ABL1*\n9813 B-lymphoblastic leukemia/lymphoma with t(v;11q23.3); *KMT2A*-rearranged\n9814 B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1); *ETV6-RUNX1*\n9815 B-lymphoblastic/lymphoma with hyperdiploidy\n9816 B-lymphoblastic/lymphoma with hypodiploidy (hypodiploid ALL)\n9817 B-lymphoblastic/lymphoma with t(5;14)(q31.1;q32.1); IGH/*IL3*\n9818 B-lymphoblastic/lymphoma with t(1;19)(q23;p13.3); *TCF3-PBX1*\n9820 Lymphoid leukemia, NOS\n9831 T-cell large granular lymphocytic leukemia\n9832 Prolymphocytic leukemia, NOS\n9833 B-cell prolymphocytic leukemia\n9834 T-cell prolymphocytic leukemia\n9837 T-lymphoblastic leukemia/lymphoma \n9840 Pure erythroid leukemia\n9860 Myeloid leukemia, NOS\n9861 Acute myeloid leukemia, NOS\n9863 Chronic myeloid leukemia\n9865 Acute myeloid leukemia with t(6;9)(p23;q34.1); *DEK-NUP214*\n9866 Acute promyelocytic leukemia with *PML-RARA*\n9867 Acute myelomonocytic leukemia\n9869 Acute myeloid leukemia with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26;2); *RBM15-MKL1*\n9870 Acute basophilic leukemia\n9871 Acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); *CBFB-MYH11*\n9872 Acute myeloid leukemia, minimal differentiation\n9873 Acute myeloid leukemia without maturation\n9874 Acute myeloid leukemia with maturation\n9875 Chronic myeloid leukemia, *BCR-ABL1*-positive\n9876 Atypical chronic myeloid leukemia *BCR-ABL1*-negative\n9891 Acute monoblastic and monocytic leukemia\n9895 Acute myeloid leukemia with myelodysplasia-related changes\n9896 Acute myeloid leukemia with t(8;21)(q22;q22.1), *RUNX1-RUNX1T1*\n9897 Acute myeloid leukemia with t(9;11)(p21.3;q23.3); *KMT2A-MLLT3*\n9898 Myeloid leukemia associated with Down Syndrome\n9910 Acute megakaryoblastic leukemia\n9911 Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13.3;q13.1); *RBM15-MKL1*\n9920 Therapy-related myeloid neoplasms\n9931 Acute panmyelosis with myelofibrosis\n9940 Hairy cell leukemia\n9945 Chronic myelomonocytic leukemia, NOS\n9946 Juvenile myelomonocytic leukemia\n9948 Aggressive NK-cell leukemia\n9950 Polycythemia vera\n9961 Primary myelofibrosis\n9962 Essential thrombocythemia\n9963 Chronic neutrophilic leukemia\n9964 Chronic eosinophilic leukemia, NOS\n9965 Myeloid/lymphoid neoplasms with *PDGFRA* rearrangement\n9966 Myeloid/lymphoid neoplasm with *PDGFRB* rearrangement\n9967 Myeloid/lymphoid neoplasm with *FGFR1* rearrangement\n9975 Myelodysplastic/myeloproliferative neoplasm, unclassifiable\n9980 Myelodysplastic syndrome with single lineage dysplasia\n9982 Myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia\n9983 Myelodysplastic syndrome with excess blasts\n9985 Myelodysplastic syndrome with multilineage dysplasia\n9986 Myelodysplastic syndrome with isolated del(5q)\n9989 Myelodysplastic syndrome, unclassifiable\n9991 Refractory neutropenia\n9992 Refractory thrombocytopenia\n\n**Note 5:** Summary Stage is the only applicable staging system for this site/histology/schema.\n\n**Note 6:** Codes 0, 2, 3, 4, and 5 are not applicable for this schema.",
  "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 3-30\n\n(5) **Introduction to Hematologic Malignancies**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 931-935\n\n(6) Radich, J.P., Jaffe, E.S., Leonard, J.P., et al. **Leukemia**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 979-997",
  "last_modified" : "2018-03-12T16:39:57.626Z",
  "definition" : [ {
    "key" : "ss2018",
    "name" : "SS2018",
    "type" : "INPUT"
  }, {
    "key" : "description",
    "name" : "Description",
    "type" : "DESCRIPTION"
  } ],
  "rows" : [ [ "1", "Localized only\n- Localized disease\n- (Single/solitary/unifocal/isolated)\n- See Notes 2 and 3" ], [ "7", "Distant site(s)/lymph node(s) involved\n- Systemic disease\n- See Note 4" ], [ "9", "Unknown if extension or metastasis" ] ]
}